New drug duo aims to shrink oral tumors before surgeons operate
NCT ID NCT07484139
Summary
This study is testing whether giving two drugs, XL-092 and pembrolizumab, before surgery can better shrink or eliminate tumors in people with a specific type of oral cavity cancer that is not linked to HPV. The goal is to see if this combination leads to more patients having little to no cancer left by the time of their surgery, compared to standard treatments. The trial will enroll about 26 adults with this type of cancer that is still operable.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University
Atlanta, Georgia, 30322, United States
Contact Email: •••••@•••••
Contact
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.